Assessment of Cyto/Genotoxicity of Irinotecan in V79 Cells Using the Comet, Micronucleus, and Chromosome Aberration Assay

Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.10.1016/S0021-9258(17)38654-4Search in Google Scholar

Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.Search in Google Scholar

Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-38.10.1021/bi00437a018Search in Google Scholar

Kjeldsen E, Svejstrup JQ, Gromova H, Alsner J, Westergaard O. Camptothecin inhibits both the cleavage and religation reactions of eucaryotic DNA topoisomerase I. J Mol Biol 1992;228:1025-30.10.1016/0022-2836(92)90310-GSearch in Google Scholar

Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003;45:91-108.10.1016/S1040-8428(02)00090-2Search in Google Scholar

Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.Search in Google Scholar

Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.10.1093/jnci/85.4.271Search in Google Scholar

Rothenberg ML, Kuhn JG, Schaf LJ, Drengler RL, Eckhardt SG, Villalonacalero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Vonhoff DD. Alternative dosing scheduels for Irinotecan. Oncology (Huntington) 1998;12(Suppl 6):68-71.Search in Google Scholar

Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972;32:2643-50.Search in Google Scholar

Irinotecan. USP DI. Vol. 1, Drug information for the health care professional. 20^th ed. Englewood (CO): Micromedex Inc.; 2000.Search in Google Scholar

Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.10.1016/0014-4827(88)90265-0Search in Google Scholar

Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS. Preclinical and clinical results with Irinotecan - extending principles learned in model system to clinical trails design. Oncology (Williston Park). 1998;12(8 Suppl 6):84-93.Search in Google Scholar

Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 1993;84:566-73.10.1111/j.1349-7006.1993.tb00177.x59191778391526Search in Google Scholar

Kopjar N, Želježić D, Lucić Vrdoljak A, Radić B, Ramić S, Milić M, Gamulin M, Pavlica V, Fučić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol 2007;100:403-13.10.1111/j.1742-7843.2007.00068.x17516995Search in Google Scholar

Sánchez-Alcázar JA, Bradbury DA, Brea-Calvo G, Navas P, Knox AJ. Camptothecin-induced apoptosis in non-small cell lung cancer is independent on cyclooxygenase expression. Apoptosis 2003;8:639-47.10.1023/A:1026147812000Search in Google Scholar

Ciesielski MJ, Fenstermaker RA. Synergistic cytotoxicity, apoptosis and protein linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorilation. J Neurooncol 1999;41:223-34.10.1023/A:1006129119460Search in Google Scholar

Minderman H, Conroy JM, O Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Therap 2005;4:885-900.10.1158/1535-7163.MCT-04-0048Search in Google Scholar

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anti-Cancer Drugs 2001;12:741-51.10.1097/00001813-200110000-00006Search in Google Scholar

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroentrol Hepatol 2003;18:1095-100.10.1046/j.1440-1746.2003.03136.xSearch in Google Scholar

Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-7.10.1023/A:1021061306913Search in Google Scholar

Daza P, Torreblanca J, Garcia-Herdugo G, Moreno FJ. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells. Cell Biol Int 2002;26:707-13.10.1006/cbir.2002.0924Search in Google Scholar

Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002;520:47-56.10.1016/S1383-5718(02)00174-2Search in Google Scholar

Gradzka I, Skierski J, Szumiel I. DNA repair, cell cycle progression and cell death following Camptothecin treatment in two murine lymphoma L5178Y sublines. Cell Biochem Funct 1998;16:239-52.10.1002/(SICI)1099-0844(1998120)16:4<239::AID-CBF792>3.0.CO;2-TSearch in Google Scholar

Ollikainen T, Knuuttila A, Suhonen S, Taavitsainen M, Jekunen A, Mattson K, Linnainmaa K. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs 2000;11:93-9.10.1097/00001813-200002000-00005Search in Google Scholar

Anderson RD, Berger NA. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994;309:109-42.10.1016/0027-5107(94)90048-5Search in Google Scholar

Voight W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM. Topoisomerase- I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 1998;18(5A):3499-505.Search in Google Scholar

Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;193:27-35.10.1016/0014-4827(91)90534-2Search in Google Scholar

Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G₂ arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52:1823-9.Search in Google Scholar

Mahabir AG, Benthem Jv, Korsten H, Lynch AM, Bailey L, de Vries A, Hendriksen CF, van Steeg H. Detecting genotoxic effects of potential clastogens: An in vivo study using the transgenic lacZ plasmid and the MutaTM Mouse model. Mutat Res 2008;652:151-7.10.1016/j.mrgentox.2008.01.007Search in Google Scholar

Holmström M, Winters V. Micronuclei induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice. Mutagenesis 1992;7:189-93.10.1093/mutage/7.3.189Search in Google Scholar

Bacher LC, Allen JW, Harrington-Brock K, Campbell JA, Moore MM. Genotoxicity of inhibitors of DNA topoisomerase I (camptothecin) and II (m-ASA) in vivo and in vitro. Mutagenesis 1990;5:541-7.10.1093/mutage/5.6.541Search in Google Scholar

Hardman WE, Moyer MP, Cameron IL. Consumption of an omege-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983-8.10.1038/sj.bjc.6600175Search in Google Scholar

Aydemir N, Bilaloglu R. Genotoxicity of two anticancer drugs; gentamicine and topotecan, in mouse bone marrow in vivo. Mutat Res 2003;537:43-51.10.1016/S1383-5718(03)00049-4Search in Google Scholar

Attia SM, Aleisa AM, Bakheet SA, Al-Yahya AA, Al-Reyaie SS, Ashour AE, Al-Shabanah OA. Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan and irinotecan. Environ Mol Mutegen 2009;50:145-51.10.1002/em.2046019152382Search in Google Scholar